Security
AMGN · Amgen Inc
40 institutional holder(s) · 40 congressional trade(s)
Amgen is one of the largest biotechs, selling drugs across inflammation, oncology, and bone health, including Enbrel and Repatha. It acquired Horizon Therapeutics for its rare-disease drugs. It is held by 11 of 26 tracked funds in the latest quarter and traded by 19 members of Congress in disclosed filings.
Institutional holders
13F
| Fund | Value | Shares |
|---|
| Vanguard Group |
$16.14B | 49,325,180 |
| State Street |
$10.75B | 30,548,488 |
| BlackRock |
$6.25B | 17,761,735 |
| Geode Capital Management |
$4.82B | 13,733,719 |
| BlackRock |
$3.95B | 11,230,082 |
| Morgan Stanley |
$2.83B | 8,029,368 |
| BlackRock |
$2.14B | 6,096,337 |
| Morgan Stanley |
$1.06B | 3,014,917 |
| Vanguard Group |
$1.01B | 3,071,496 |
| Bank of America |
$983.6M | 2,795,619 |
| Fidelity |
$749.9M | 2,131,329 |
| Morgan Stanley |
$719.5M | 2,044,807 |
| Geode Capital Management |
$597M | 1,696,805 |
| BlackRock |
$566.9M | 1,611,071 |
| BlackRock |
$521.7M | 1,482,775 |
| BlackRock |
$435.1M | 1,236,622 |
| BlackRock |
$398.6M | 1,132,897 |
| Vanguard Group |
$384.9M | 1,175,817 |
| Morgan Stanley |
$372.8M | 1,059,658 |
| BlackRock |
$370.2M | 1,052,085 |
| Fidelity |
$365.5M | 1,038,811 |
| Bank of America |
$351M | 997,550 |
| BlackRock |
$337.5M | 959,278 |
| BlackRock |
$336.7M | 956,841 |
| Vanguard Group |
$328.2M | 1,002,862 |
| Bank of America |
$323.8M | 920,334 |
| BlackRock |
$321.8M | 914,522 |
| Morgan Stanley |
$270.6M | 769,113 |
| BlackRock |
$270.2M | 767,967 |
| Citadel Advisors |
$261.6M | 743,500 |
| Citadel Advisors |
$216.6M | 615,500 |
| Fidelity |
$207.1M | 588,736 |
| BlackRock |
$206.6M | 587,153 |
| BlackRock |
$188.9M | 536,819 |
| Morgan Stanley |
$161.2M | 458,177 |
| Bank of America |
$101.3M | 287,836 |
| Millennium Management |
$96.4M | 274,100 |
| Millennium Management |
$87.7M | 249,200 |
| Vanguard Group |
$84.9M | 259,315 |
| Morgan Stanley |
$82.4M | 234,198 |
Congressional trades
STOCK Act